BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1427@pharmaconomics
DTSTAMP:20260707T033943Z
DTSTART;VALUE=DATE:20260319
DTEND;VALUE=DATE:20260320
SUMMARY:IFRX Phase 2 — izicopan
DESCRIPTION:Phase 2 trial results for izicopan in ANCA-associated vasculitis are due Mar 19\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1708688/000121390026031549/ea028182101ex99-1.htm\n\nTrack it: https://pharmaconomics.com/e/1427
URL:https://pharmaconomics.com/e/1427
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:IFRX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR